The Switzerland-based Company is slated to release top line results of its phase IIb clinical trial of Linzagolix (OBE2109), its novel oral GnRH receptor antagonist, for the treatment of endometriosis-associated pain on Monday June 18, 2018, before the market opens.
Endometriosis is a condition in which the tissue that normally lines the uterus grows outside the uterus. Its primary symptoms include pain and infertility. (Source: NIH). It is estimated that more than 11% of American women between 15 and 44 have this condition.
The trial dubbed EDELWEISS has enrolled about 330 patients. The primary endpoint is patient response following 12 weeks of treatment, defined as at least 30% improvement in combined menstrual and non-menstrual pain as measured by a four point verbal rating scale (VRS).
Will EDELWEISS hit the trial goals?
OBSV has traded in a range of $5.00 to $15.81 over the last 1 year. The stock closed Friday's trading at $14.55, down 3%.
At around 7.00 am, the Company announced that its EDELWEISS trial achieved the primary and secondary endpoints.
We had alerted our premium subscribers to this stock on July 9, 2017, when it was trading around $7.82. The stock is currently up more than 9% at $16 in today's pre-market trading.
For comments and feedback contact: firstname.lastname@example.org
Source : http://www.rttnews.com/2905855/what-awaits-obseva-pain-or-gain.aspx276